Molecular pathogenesis of spinal and bulbar muscular atrophy

被引:15
|
作者
Merry, DE [1 ]
机构
[1] Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA
关键词
androgen receptor; polyglutamine; Kennedy's disease; protein aggregation;
D O I
10.1016/S0361-9230(01)00594-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Studies of the molecular pathogenesis of spinal and bulbar muscular atrophy, as well as of the other polyglutamine repeat diseases, has led to an understanding of the role of protein accumulation in disease pathogenesis. Aggregation of the expanded repeat androgen receptor (AR), rather than playing a pathogenic role, likely reflects the insoluble nature of the misfolded AR. Proteolytic processing of the expanded AR at various stages of its metabolism may contribute to cellular toxicity through the enhancement of AR insolubility, and potentially through the disruption of normal proteolytic degradation processes. The finding that molecular chaperones not only promote solubility, but also enhance the degradation of expanded polyglutamines as well, make them promising targets for therapeutic development. Understanding the role of ligand binding in expanded AR metabolism may provide additional avenues of therapeutic manipulation as well. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 50 条
  • [1] Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy
    Adachi, H.
    Waza, M.
    Katsuno, M.
    Tanaka, F.
    Doyu, M.
    Sobue, G.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2007, 33 (02) : 135 - 151
  • [2] Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA)
    Haruhiko Banno
    Masahisa Katsuno
    Keisuke Suzuki
    Fumiaki Tanaka
    Gen Sobue
    Cell and Tissue Research, 2012, 349 : 313 - 320
  • [3] Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA)
    Banno, Haruhiko
    Katsuno, Masahisa
    Suzuki, Keisuke
    Tanaka, Fumiaki
    Sobue, Gen
    CELL AND TISSUE RESEARCH, 2012, 349 (01) : 313 - 320
  • [4] Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)
    Katsuno, Masahisa
    Tanaka, Fumiaki
    Adachi, Hiroaki
    Banno, Haruhiko
    Suzuki, Keisuke
    Watanabe, Hirohisa
    Sobue, Gen
    PROGRESS IN NEUROBIOLOGY, 2012, 99 (03) : 246 - 256
  • [5] Spinal and bulbar muscular atrophy: pathogenesis and clinical management
    Grunseich, C.
    Rinaldi, C.
    Fischbeck, K. H.
    ORAL DISEASES, 2014, 20 (01) : 6 - 9
  • [6] Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment
    Grunseich, Christopher
    Fischbeck, Kenneth H.
    CURRENT OPINION IN NEUROLOGY, 2020, 33 (05) : 629 - 634
  • [7] Molecular diagnosis of spinal and bulbar muscular atrophy in Slovakia
    Zelinkova, H.
    Kolejakova, Lexova K.
    Spalek, P.
    Chandoga, J.
    Konkolova, J.
    Bohmer, D.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2016, 117 (03): : 137 - 141
  • [8] Spinal and Bulbar Muscular Atrophy
    Grunseich, Christopher
    Fischbeck, Kenneth H.
    NEUROLOGIC CLINICS, 2015, 33 (04) : 847 - +
  • [9] Spinal and bulbar muscular atrophy: From molecular pathogenesis to pharmacological intervention targeting skeletal muscle
    Marchioretti, Caterina
    Andreotti, Roberta
    Zuccaro, Emanuela
    Lieberman, Andrew P.
    Basso, Manuela
    Pennuto, Maria
    CURRENT OPINION IN PHARMACOLOGY, 2023, 71
  • [10] Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA)
    Suzuki, Keisuke
    Kastuno, Masahisa
    Banno, Haruhiko
    Sobue, Gen
    NEUROPATHOLOGY, 2009, 29 (04) : 509 - 516